200 related articles for article (PubMed ID: 28655809)
1. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
Ferrero S; Dreyling M;
Haematologica; 2017 Jul; 102(7):1133-1136. PubMed ID: 28655809
[No Abstract] [Full Text] [Related]
2. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of mantle cell lymphoma in the primary setting.
Tang C; Kuruvilla J
Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
[No Abstract] [Full Text] [Related]
4. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Dreyling M; Ferrero S;
Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
[TBL] [Abstract][Full Text] [Related]
5. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Liu H; Johnson JL; Koval G; Malnassy G; Sher D; Damon LE; Hsi ED; Bucci DM; Linker CA; Cheson BD; Stock W
Haematologica; 2012 Apr; 97(4):579-85. PubMed ID: 22102709
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
7. SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?
Simonsen AT; Schou M; Sørensen CD; Bentzen HH; Nyvold CG
Leuk Lymphoma; 2015; 56(9):2724-7. PubMed ID: 25629991
[No Abstract] [Full Text] [Related]
8. Clinical Management Updates in Mantle Cell Lymphoma.
Chen R; Sanchez J; Rosen ST
Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
[TBL] [Abstract][Full Text] [Related]
9. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
10. Optimal frontline management of mantle cell lymphoma: can we agree?
Tang C; Kuruvilla J
Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
[No Abstract] [Full Text] [Related]
11. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
12. The role of SOX11 in mantle cell lymphoma.
Lu TX; Li JY; Xu W
Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
[TBL] [Abstract][Full Text] [Related]
13. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
14. Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Jung D; Jain P; Yao Y; Wang M
J Hematol Oncol; 2020 Sep; 13(1):127. PubMed ID: 32972438
[TBL] [Abstract][Full Text] [Related]
15. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
[TBL] [Abstract][Full Text] [Related]
17. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Amador V; Callanan M; Jerkeman M; Le Gouill S; Pott C; Rule S; Zaja F;
Leuk Lymphoma; 2015 Apr; 56(4):866-76. PubMed ID: 25015778
[TBL] [Abstract][Full Text] [Related]
18. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.
Dreyling M; Ferrero S;
Haematologica; 2015 Jun; 100(6):706-8. PubMed ID: 26034112
[No Abstract] [Full Text] [Related]
19. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.
Gimenez E; Chauvet M; Rabin L; Puteaud I; Duley S; Hamaidia S; Bruder J; Rolland-Neyret V; Le Gouill S; Tournilhac O; Voog E; Maisonneuve H; Jacob MC; Leroux D; Béné MC; Formisano-Tréziny C; Gabert J; Gressin R; Callanan MB
Br J Haematol; 2012 Jul; 158(2):186-197. PubMed ID: 22626453
[TBL] [Abstract][Full Text] [Related]
20. Update in the management of mantle cell lymphoma.
Goy A
Clin Adv Hematol Oncol; 2013 May; 11(5):297-9. PubMed ID: 23880713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
